Global Investor Forum Contact

Mirjam Mol

CEO, Pivot Park


11:30 - 12:45 hours
From innovation to implementation

Mirjam Mol-Arts was appointed on October 1, 2014 as CEO of Pivot Pivot Park and Pivot Park Screening Centre. Mirjam is an honors graduate in medicine from the University of Utrecht. She has a sound medical scientific background and has worked in various hospitals in the Netherlands until 1989, when she switched to pharma to the clinical development group in Solvay Duphar. In 1997 Mirjam started as Clinical Development Director at Organon and in 2001 she became head of the Women's Health Programme. Since 2011, she was part of the Dutch management of MSD, which merged with Schering-Plough, worldwide in 2009 and was chair of the local management of MSD in Oss. She was closely involved in the creation of Pivot Park and was part of the Task Force Life Sciences Park Oss. Mirjam is also a member of the Steering Committee of the Dutch Topsector Life Sciences & Health (Health Holland) and a member of the board of Health Valley.

Since January 1st 2018 Mirjam is Senior Vice President Global Clinical and Non-Clinical development at Ferring in Kopenhagen.


Pivot Park: hotspot for pharmaceutical innovation
Pivot Park is an inspiring campus for (open) innovation in the life sciences with a focus on pharmaceutical Research, Development and Production. It is the perfect place for start-ups and existing companies to accelerate, grow and succeed.
Pivot Park was launched in February 2012 as an initiative of pharmaceutical company MSD in close collaboration with five public partners after closure of the MSD Oss R&D group.
‘Pivot’ means axis or central point, and that’s exactly the role that Pivot Park wants to fulfil on a daily basis for dynamic life sciences companies. How? By offering state-of-the-art core facilities and infrastructure, the flexibility to deliver customised work to ambitious entrepreneurs in the life sciences sector and an inspiring community. Several companies at Pivot Park were successful, starting of as a small company and scaled-up to over 25 and some of them over 50 employees, and delivering new treatment options to patients.
How can we, especially on a national level, facilitate entrepreneurs/researchers with great ideas in the life sciences in close collaboration with public and private stakeholders to ensure that these innovations can turn in to solutions which contribute to a healthier society.
Niels Chavannes
Maarten van Dongen
Ingmar de Gooijer
Mark van Houdenhoven
Sint Maartenskliniek

Henk van Houten

Arthur Lahr
Kiadis Pharma

Jos Malda
UMC Utrecht
Eveliene Manten-Horst
AYA Jongvolwassen & Kanker

Madelon Maurice
UMC Utrecht

Tom Miller
GreyBird Ventures
Edwin Moses
Kees Recourt
Mibiton Foundation

Maurits van Selms

Marianne van der Steen
Markwin Velders
Kite Pharma
Werner Verbiest
Janssen Diagnostics
Eline Vrijland-van Beest
Sponsors & Partners
Main partner
Host sponsor
Host sponsor
Host sponsor
Platinum sponsor
Gold sponsor
Award sponsor
Your logo?
© 2018 Innovation for Health